Nurix Therapeutics (NRIX) Total Liabilities (2019 - 2025)
Historic Total Liabilities for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $149.4 million.
- Nurix Therapeutics' Total Liabilities rose 494.42% to $149.4 million in Q4 2025 from the same period last year, while for Nov 2025 it was $149.4 million, marking a year-over-year increase of 494.42%. This contributed to the annual value of $149.4 million for FY2025, which is 494.42% up from last year.
- As of Q4 2025, Nurix Therapeutics' Total Liabilities stood at $149.4 million, which was up 494.42% from $150.2 million recorded in Q3 2025.
- Over the past 5 years, Nurix Therapeutics' Total Liabilities peaked at $155.1 million during Q4 2023, and registered a low of $74.4 million during Q3 2023.
- Moreover, its 5-year median value for Total Liabilities was $133.0 million (2022), whereas its average is $127.3 million.
- In the last 5 years, Nurix Therapeutics' Total Liabilities plummeted by 3631.64% in 2023 and then skyrocketed by 8385.01% in 2024.
- Nurix Therapeutics' Total Liabilities (Quarter) stood at $134.5 million in 2021, then decreased by 15.92% to $113.1 million in 2022, then surged by 37.18% to $155.1 million in 2023, then decreased by 8.22% to $142.4 million in 2024, then increased by 4.94% to $149.4 million in 2025.
- Its Total Liabilities stands at $149.4 million for Q4 2025, versus $150.2 million for Q3 2025 and $144.0 million for Q2 2025.